XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization
XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...
Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda
Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...
China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings
The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...
DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix
South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to...
KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities
KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...
Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China
Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...
Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...
Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...
Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial
Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...
EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval
EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...
FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site
The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development
China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...
AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market
AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...
Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia
Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...